Aspire Biopharma signs LOI to acquire automotive supplier DCS for $30M; DCS had $200M+ revenue in FY2025

Aspire Biopharma Holdings, Inc.

Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).
DCS is a tier-one auto supplier with 310 patents, 11 global facilities, serving 150+ vehicle platforms across major OEMs.
Management from Lakewood & Company (100+ years auto experience) to bolster DCS leadership; deal subject to due diligence and audit.
RBW Capital Partners is exclusive financial advisor; Dawson James Securities will provide brokerage services for the acquisition.
Aspire plans to become a diversified, high-revenue enterprise; no definitive agreement executed yet and no assurance of completion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.